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Abstract: (1) Background: Cantu syndrome (CS) arises from gain-of-function (GOF) mutations in
the ABCC9 and KCNJ8 genes, which encode ATP-sensitive K+ (KATP) channel subunits SUR2 and
Kir6.1, respectively. Most CS patients have mutations in SUR2, the major component of skeletal
muscle KATP, but the consequences of SUR2 GOF in skeletal muscle are unknown. (2) Methods:
We performed in vivo and ex vivo characterization of skeletal muscle in heterozygous SUR2[A478V]
(SUR2wt/AV) and homozygous SUR2[A478V] (SUR2AV/AV) CS mice. (3) Results: In SUR2wt/AV and
SUR2AV/AV mice, forelimb strength and diaphragm amplitude movement were reduced; muscle
echodensity was enhanced. KATP channel currents recorded in Flexor digitorum brevis fibers showed
reduced MgATP-sensitivity in SUR2wt/AV, dramatically so in SUR2AV/AV mice; IC50 for MgATP
inhibition of KATP currents were 1.9 ± 0.5 × 10−5 M in SUR2wt/AV and 8.6 ± 0.4 × 10−6 M in WT
mice and was not measurable in SUR2AV/AV. A slight rightward shift of sensitivity to inhibition
by glibenclamide was detected in SUR2AV/AV mice. Histopathological and qPCR analysis revealed
atrophy of soleus and tibialis anterior muscles and up-regulation of atrogin-1 and MuRF1 mRNA
in CS mice. (4) Conclusions: SUR2[A478V] “knock-in” mutation in mice impairs KATP channel
modulation by MgATP, markedly so in SUR2AV/AV, with atrophy and non-inflammatory edema in
different skeletal muscle phenotypes.
Keywords: ATP-sensitive potassium channel; Cantu syndrome; glibenclamide; histopathology;
patch-clamp; rare disease; skeletal muscle
1. Introduction
Cantu syndrome (CS, OMIM#239850) is a rare condition characterized by cardiovas-
cular alterations, skeletal abnormalities and excess hair growth [1], as well as neurological
alterations and skeletal muscle dysfunction [2,3]. CS arises from missense mutations in
KCNJ8 or ABCC9 genes, which encode Kir6.1 and SUR2 subunits, respectively, of ATP-
sensitive potassium (KATP) channels. In vitro experiments have revealed that CS mutations
are responsible for a gain-of-function (GOF) of the channel, linked to increased open state
stability, reduced sensitivity to inhibitory MgATP or increased sensitivity to MgADP [4–8].
Currently, there is no targeted therapy for CS.
Most identified CS mutations are in ABCC9; the recently published International Cantu
Syndrome Registry reports that 72 of the 74 described patients have confirmed ABCC9
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variants [3]. Several skeletal muscle abnormalities stand out among the large variety of
symptoms these patients have reported, including thin or even quite muscular physique
during childhood and delays in the development of normal motor skills. Around 70% of
these patients have also reported skeletal muscle hypotonia in adulthood, associated with
hypermobile joints and exercise intolerance [3]. KATP channels have a key protective role
in skeletal muscle, and alteration of their function has previously been related with sev-
eral pathologic conditions. By opening in response to reduced [ATP]/[ADP] ratio, KATP
channels may reduce skeletal muscle excitability and induce fatigue, thereby avoiding
exercise-induced muscle damage [9,10]. Consistent with this concept, activation of KATP
channels by the agonist pinacidil increases the rate of fatigue in fast- or slow-twitch mice
skeletal muscle [11]. Conversely, reducing KATP channels with inhibitory sulfonylureas
causes fiber death and atrophy [12–14], and down-regulation of WT sarco-KATP chan-
nel activity underlies primary and secondary forms of hypokalemic periodic paralysis,
transient weakness and hypokalemia [15].
We previously showed that CS mice carrying the GOF Kir6.1 mutation V65M exhibit
serious skeletal muscle defects in type I fibers, including atrophy with fibrotic replacement,
up-regulation of autophagy genes and reduced muscle strength, in addition to signifi-
cant cardiovascular pathologies, resembling those seen in human CS [16]. Importantly,
while Kir6.1 (and SUR1) contributes to skeletal muscle KATP channels, Kir6.2 pore-forming
subunits with SUR2A sulfonylurea receptors are the major components [17]. In the present
study, we evaluated the effects induced by a SUR2 CS mutation (A478V) on the skele-
tal muscle of heterozygous SUR2[A478V] (SUR2wt/AV) and homozygous SUR2[A478V]
(SUR2AV/AV) mice by combined in vivo and ex vivo experiments. Although these mice
exhibit less severe vascular defects than Kir6.1[V65M] mice [18,19], the skeletal muscle
phenotype was more striking. This is consistent with the more prominent role of SUR2A in
generating skeletal muscle channels and suggests that skeletal muscle consequences are
likely to be more profound in human CS patients with ABCC9 versus KCNJ8 mutations.
2. Materials and Methods
2.1. Animal Care
CRISPR/Cas9 gene editing was used to introduce single-nucleotide mutations into
the endogenous ABCC9 gene locus, resulting in protein substitutions that are analogous
to SUR2[A478V] (A476V in mouse sequence) in human CS patients [18]. Heterozygous
SUR2[A478V] mice (SUR2wt/AV) and homozygous SUR2[A478V] (SUR2AV/AV) mice geno-
type was verified by Sanger sequencing of genomic DNA, as previously described [18].
Since no evidence of gender differences currently exist in CS [3], only male mice were used
for our experiments. Pathogen-free mice were imported from Washington University in
Saint Louis, under approved protocols at the Stabulario of the Dipartimento di Farmacia-
Scienze del Farmaco, University of Bari, Bari, Italy, under the supervision of the veterinary
officer in accordance with D.lgs. 26/2014. Mice were maintained 2–4 per cage and were
provided with a standard laboratory diet and water ad libitum. Laboratory was kept at
50 ± 5% relative humidity and at a temperature of 22 ± 1 ◦C, under 12:12 light/dark cycles.
2.2. Ethical Statements
All the applied experimental protocols and the animal care were in harmony with the
European Directive 2010/63/EU on Animal Protection Used for Scientific Experiments, as
well as with the Washington University School of Medicine Institutional Animal Care and
use Committee, and were approved by the Italian Ministry of Health and by the Committee
of the University of Bari O.P.B.A (Organization for Animal Health) (prot. 8515-X/10,
30 January 2019). The animal sample size (number of mice needed) was calculated as the
minimum required to reach statistical significance according to the 3R “Replace, Reduce,
Refine” rules. The sample size was calculated using the comparisons between WT mice and
CS mice performed by the t-test between two independent means (two groups) to evaluate
variance between groups. The p value was considered statistically significant if lower than
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0.05. The calculation was performed according to the approved protocol by our Ethical
Committee for animal experiments, O.P.B.A. of the University of Bari. The calculation of
the sample was made assuming a delta change of the KATP current amplitude = 300 pA in
excised patch experiments performed on FDB fibers of the transgenic mice Kir6.1wt/VM vs.
WT mice [16] using G * Power 3.1.9.2. The calculation gave rise to 4 mice x genotype with a
power of 0.8.
In particular, in the present work, the primary endpoint used for the calculation of the
sample size was the delta changes of the KATP current in excised macropatches. Secondary
endpoints were the morphological and functional differences in skeletal muscle.
Assuming the input—tail(s) = two, effect size d = 1.99, α err prob = 0.05, power
(1-β err prob) = 0.8, allocation ratio N2/N1 = 1, the mean1 = 1499 pA in FDB for SUR2
homozygous mice, mean2 = 1192 pA in FDB for WT mice in patch-clamp experiments,
DS1 = 151, DS2 = 164—the output data were non-centrality parameter δ = 3.079, critical
t = 1.8595, df = 8, sample size group 1 = 4, sample size group 2 = 4, actual power = 0.8.
We had 4 mice per genotype for a total 8 CS mice and 4 WT mice.
To minimize risk of observer bias and other “experimenter effects”, experiments
were performed “blinded” when possible (for instance, homozygous mice are larger and
heavier than other genotypes), so that experimenters were unaware of the genotype of
the animals [20].
2.3. In Vivo Parameters of Muscle Strength
Evaluation of forelimb strength was performed using a grip strength meter (Columbus
Instruments, Columbus, OH, USA), according to TREAT–NMD Neuromuscular Network
SOPs (SOP ID Number: DMD_M.2.2.001) [21], by an investigator blinded to mouse geno-
type, as previously described [16]. Five separate measurements were acquired for each
animal and were averaged for the calculation of the medium strength.
2.4. Ultrasound Evaluations
Blinded ultrasonography experiments were conducted using an ultra-high frequency
ultrasound bio-microscopy system Visual Sonic (VEVO 2100, Inc. Toronto, ON, Canada).
Each animal was anesthetized via inhalation (induction with 3% isoflurane and 1.5% O2
L/min, then constantly maintained via nose cone at 1.5–2% isoflurane and 1.5% O2) and
placed on a thermostatically controlled table (kept at 37 ◦C) equipped with 4 copper leads
that allowed monitoring of heart and respiratory rate. A rectal probe was used to monitor
body temperature. The mice were prepared as previously described [22,23]. We carried out
B and M mode diaphragm echodensity measurements using a MS250 probe operating at a
frequency of 21 MHz and characterized by lateral and axial resolutions of 165 and 75 mm,
respectively. The image acquisition was performed placing the probe along the transverse
mid-sternal axis of the mouse. B mode acquisition was used to perform echodensity
measurements of the diaphragm and analyzed using ImageJ® software (V1.8.0, Softonic Int.,
Barcelona, Spain) by creating a grey scale analysis histogram on entire outlined diaphragm
sections and on hind limb sections of a constant dimensions of 3653.25 ± 9.75 pixels
and of 7392.12 ± 18.45 pixels, respectively. Echodensity differences were expressed as
the percentage change of the mean echodensity of all pixels included in the selected
area. M mode acquisition was used to measure the amplitude of the diaphragm during
normal breathing cycles on the left side of the diaphragm to minimize variability in the
measurements. The amplitude of the diaphragm movement during each inspiration
(positive deflection) was measured as the distance, in millimeters, between the baseline
and the peak of the contraction for each mouse; the diaphragm amplitude movement was
obtained from the average of three to five measurements [24].
Ultrasound acquisitions of the hind limb were performed to evaluate total hind limb
volume (in mm3) and percentage of vascularization (PV%). A 3-dimensional (3D) volume
scan of the hind limbs was acquired by translating the ultrasound probe parallel to the
long axis of the hind limb. Multiple 2D images were acquired at regular intervals in Power
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Doppler mode. At the end of the procedure, 3D images were reconstructed from previously
collected multiple 2D frames and were visualized with VisualSonics 3D software (VEVO
3100, Toronto, ON, Canada) [25].
2.5. Animal Sacrifice and Tissue Collection
Animals were sacrificed by cervical dislocation under ZOLETIL 50/50 (40 mg/kg
i.p.) profound anesthesia [26]. Tissues and organs were isolated while keeping the animal
under profound anesthesia, using sterilized equipment under a sterile cell culture hood to
avoid contamination. Blot-dried organs were weighed; weights were normalized to the
tibia length.
2.6. Drugs and Solutions
Muscle and organ biopsies were carried out in Ringer’s solution: 145 mM NaCl,
5 mM KCl, 1 mM MgCl2, 0.5 mM CaCl2, 5 mM glucose and 10 mM 3-(N-morpholino)
propanesulfonate (MOPS) sodium salt (pH = 7.2 with MOPS acid). For patch-clamp
experiments, pipette solution contained 150 mM KCl, 2 mM CaCl2 and 1 mM MOPS
(pH 7.2); the bath solution contained 150 mM KCl, 5 mM EGTA and 10 mM MOPS (pH
7.2). Stock solution of glibenclamide (Glib) at a concentration of 118.6 mM was prepared
by dissolving the drug in dimethyl sulfoxide (DMSO); diluted solutions were prepared
using the cell medium or the bath solution, according to the use. DMSO was found not to
affect the channel currents or fiber viability at the maximal concentration tested [27].
2.7. Patch-Clamp Experiments
Patch-clamp experiments on Flexor digitorum brevis (FDB) fibers were performed in
inside-out configuration [28]. Fibers were isolated by enzymatic digestion of the muscle
with ~0.5 mg/mL collagenase (C9697, Sigma-Aldrich S.R.L, Milan, Italy). Currents were
recorded soon after isolation during voltage steps from a holding potential of 0 mV to
−60 mV (Vm) at a 1 kHz sampling rate (filter 0.2 kHz) at room temperature (20–22 ◦C),
using an Axopatch-1D amplifier equipped with a CV-4 head-stage. Current amplitude
was measured using Clampfit 10.0 (Molecular Devices, LCC, San Jose, CA, USA). Patch
pipettes for excised macropatches were pulled from borosilicate glass capillaries (Glass
type 8250, King Precision Glass, Inc. 177 S. Indian Hill Blvd. Claremont, CA, USA) and
fire-polished to a final resistance of 1.1 ± 0.1 MΩ. Macropatches containing significant
voltage-dependent K+ channels or other Kir channels or showing marked loss of channel
currents during the time of observation were excluded from the analysis. No correction
for liquid junction potential was made, estimated to be <1.9 mV under our experimental
conditions. At least 3 FDB muscles per genotypes were used for patch-clamp experiments
from different mice.
2.8. Histopathological Analysis
An autopsy with macroscopic observation of all organs was performed among the
sacrificed subjects according to approved protocols [29]. After animal sacrifice, tissue sam-
ples were incorporated, frozen in liquid nitrogen at −80 ◦C, sectioned using a cryostat
for ATPase and succinodehydrogenase (SDH) staining. Other samples were fixed with
10% animal buffered formalin for a minimum period of 72 h. Tissues were embedded in
paraffin; sections were cut to 5 µm and stained with standard techniques with hematoxylin
and eosin (H.E.), Mallory’s trichrome stain and Schiff’s periodic acid (PAS). Digital images
were taken from the cross section at 10–100× magnification to assess muscle fiber mor-
phology and to determine fiber cross-sectional area (CSA) measurements. Images from
20 random fields were acquired for the ten stained sections of each sample using a Leica
DMLS D 4000 microscope equipped with an Elements-BR-Nikon NIS camera and image
analyzer. Section analysis and CSA evaluation of the fibers were performed by QWin
software (3.1.0, Leica, Wetzlar, Germany) on 53 cells per muscle section. Examination of
cell morphology and intracellular structures was conducted, and the severity of lesions
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observed was assessed [30] by an animal pathologist blinded to the mouse genotype. At
least 2 SOL, 2 TA, 2 GA and 2 EDL muscles for histopathology analysis were used from 2
different mice per genotype.
2.9. Isolation of Total RNA, Reverse Transcription and PCR
Total RNA was isolated and purified from entire Flexor digitorum brevis (FDB), soleus
(SOL), gastrocnemius (GA) and tibialis anterior (TA) muscles with Trizol reagent (Invitro-
gen Life Technologies, Waltham, MA, USA), and was quantified using a spectrophotometer
(ND-1000 Nano-Drop, Thermo Fisher Scientific Waltham, MA, USA) For evaluating KATP
channel composition, PCR amplification was performed using PCR Master Mix (Promega
Italia S.r.l. Soc. Unip., Milan, Italy). PCR cycles consisted of denaturation at 95 ◦C for
1 min, annealing segment at 58 ◦C for 1 min, and extension at 72 ◦C for 1 min, repeated
for 30 cycles. Primer sequences were previously reported [16]. Amplified PCR products
were finally separated on 1% agarose gel. For investigating muscle damage, qPCR anal-
ysis was performed as previously described [12,23]. Probes (Life Technologies, Monza,
Italy) were ordered with the following assay IDs: FBXO32 Mm00499523_m1, TRIM63
Mm01185221_m1; Actb Mm00607939_s1. Data collection and analysis were performed
according to the MIQE [31]. At least 3 sample muscles from 3 different mice per genotype
were used.
2.10. Fiber Survival Evaluation
Survival analysis for FDB fibers was performed by an investigator blinded to mouse
genotype and treatment. Before the analysis, isolated fibers were seeded and equilibrated
in DMEM supplemented with 10% fetal bovine serum, 1% L-glutamine and 1% penicillin-
streptomycin at 37 ◦C for at least 30 min [13]. Fibers were monitored for changes in
morphological parameters such as length and diameter within 24 h after excision, using a
Nikon TMS Inverted Microscope 4× magnification. Changes of ≥40% in morphological
parameters defined dead fibers, and the appearance of multiple sarcolemma blebs was
considered a prognostic sign of cellular death. At least 3 FDB muscles per genotype from
different mice were used for cell count.
2.11. Data Analysis and Statistics
Data were collected and analyzed using Excel software (Microsoft Office 2010, Innova-
tion Campus, Milan, Italy), Clampfit 10.5 (Molecular Devices) and SigmaPlot 10.0 (Systat
Software, San Jose, CA, USA). Results are presented as mean ± SEM unless otherwise
indicated. The number of replicates relative to each experimental dataset is reported in
the figure description. One-way analysis of variance (ANOVA) followed by multiple
comparisons tests were applied (p < 0.05 unless otherwise indicated). Student t test was
applied for comparison of significance between means. Data were considered significantly
different for p < 0.05 unless otherwise specified.
For patch-clamp experiments, the percentage of KATP current inhibition induced by
glibenclamide (Glib) and MgATP was calculated with the following equation: −(ICTRL − Idrug)/
(ICTRL − Ileak) × 100, where I leak was the current recorded after the application of 5 × 10−3 M
MgATP on excised macropatches from skeletal muscle fibers.
3. Results
3.1. SUR2 CS Mice Are Heavier Than WT but Have Weaker Muscles
We first assessed the macroscopic properties of skeletal muscle in terms of strength and
integrity. Ambulatory behavior and gross musculoskeletal phenotype of CS mice were not
obviously different from wild type (WT), although 33-week-old SUR2wt/AV and SUR2AV/AV
mice were ~10% heavier than age-matched WT mice (SUR2wt/AV mice = 35.17 ± 2.21 g
(student t test p < 0.05); SUR2AV/AV mice = 33.5 ± 2.81 g (student t test p > 0.05, n.s.);
WT mice = 30.33 ± 1.25 g (n. mice per genotype = 4), while forelimb strength evaluation
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showed that both SUR2wt/AV and SUR2AV/AV mice were significantly (~10%) weaker than
WT (Figure 1A).
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3.2. Skeletal Muscles of SUR2 Mutated Mice Show Morphological and Functional Abnormalities
A 3D ultrasound evaluation of hind limb was performed to assess the morphological
differences in skeletal muscle structure. There was a progressive increase in hind limb
echodensity above that in WT, from ~20% in SUR2wt/AV mice to ~40% in SUR2AV/AV mice
(Figure 1B), indicating progressively lower muscle mass and fibrotic tissue/fat deposition
with increasing gene dose. The increased echodensity in SUR2wt/AV was paralleled by
increased hind limb volume (Figure 1D), without change in vascularization (Figure 1C).
In contrast, in SUR2AV/AV mice, hind limb volume was not markedly different from
WT (Figure 1B), but there was a striking (~60%) increase in vascularization (Figure 1C).
Ultrasound evaluation of the diaphragm revealed significant ~35% reduction in the ampli-
tude of diaphragm movement in both SUR2wt/AV and SUR2AV/AV mice, associated with
~20% and ~40% enhancement of echodensity, respectively (Figure 1E,F), again indicative of
progressively worse fat/fibrotic deposition.
Following sacrifice, individual muscles were isolated, blotted and weighed. Increased
muscle weights were observed in the heart, pectoral muscle, tibialis anterior (TA) and flexor
digitorum brevis (FDB) from SUR2wt/AV and more so from SUR2AV/AV mice. In contrast,
weight was reduced in soleus (SOL) and (non-significantly) in extensor digitorum longus
(EDL) muscles from these mice (Figure S1).
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3.3. KATP Channels in SUR2 CS Muscle Fibers Show Reduced Sensitivity to MgATP
Expression of KATP channel subunits was confirmed in fast-twitch FDB fibers by
PCR analysis of KCNJ8, KCNJ11, ABCC8 and ABBC9 genes (encoding Kir6.1, Kir6.2, SUR1
and SUR2, respectively), from FDB (n. muscles/mice = 2/2) whole muscle samples.
The presence of specific bands for KCNJ11 and ABCC9 (Figure 2A) was consistent with the
prevailing evidence that skeletal muscle KATP channels are composed predominantly of
Kir6.2/SUR2 subunits [17]. KATP channel activity was recorded in excised macropatches
using the patch-clamp technique in acutely dissociated fast-twitch FDB fibers from WT,
SUR2wt/AV and SUR2AV/AV mice. In 0 ATP bath solution, KATP current amplitude in FDB
fibers from CS mice was not significantly different from WT (Figure 2B,C). We next assessed
the nucleotide regulation of native KATP channels in FDB skeletal muscle fibers. There was
significantly reduced sensitivity to inhibition by MgATP in SUR2wt/AV fibers and more
marked reduction in SUR2AV/AV FDB fibers (Figure 3A–C, Table 1), consistent with the loss
of MgATP sensitivity expected as the mechanism for increased activity of this mutation,
based on recombinant channel activity recorded in cell lines [6].
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age of −60 mV (Vm). (A) Sample gel of PCR analysis in an FDB muscle: high levels of expression of ABCC9 and KCNJ11 
genes, encoding respectively for SUR2 and Kir6.2, were found in all the phenotypes. (B) In inside-out patch-clamp exper-
iments on FDB isolated fibers, the calculated mean was −1152.8 ± 164 pA for WT, −1381.2 ± 155.5 pA for SUR2wt/AV mice 
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Figure 2. Channel subunits expression and current amplitude distribution in FDB fibers at physiological membrane voltage
of −60 mV (Vm). (A) Sample gel of PCR analysis in an FDB muscle: high levels of expression of ABCC9 and KCNJ11 genes,
encoding respectively for SUR2 and Kir6.2, we e found in all the phenotypes. (B) In inside-out patch-cl mp experiments
on FDB isolated fibers, the calculated mean was −1152.8 ± 164 pA for WT, −1381.2 ± 155.5 pA for SUR2wt/AV mice and
−1499.2 ± 151.7 pA for SUR2AV/AV mice (n. patches = 20, 38, 45 from 3 muscles/3 mice per genotype, respectively); * data
significantly different as evaluated with one-way ANOVA and Bonferroni test for p < 0.05. (C) Sample traces of recorded
KATP currents, illustrating a tendency toward increased current amplitude in FDB fibers from SUR2wt/AV and SUR2AV/AV
mice with respect to WT but more marked reduction of sensitivity to 5 × 10−3 M MgATP.
In addition, we tested sensitivity to the KATP channel blocker glibenclamide (Glib).
Glib sensitivity was slightly decreased in channels from SUR2wt/AV FDB fibers and more
significantly so in SUR2AV/AV (Figure 3B–D, Table 1), again reflecting the minimal effect of
the mutation on glibenclamide sensitivity in recombinant channels and in other tissues [6,18].
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Figure 3. MgATP- and glibenclamide-sensitivity of rrents in FDB fibers. (A) Sample traces of currents in zero
(CTRL), 5 × 10−5 M and 5 × 10−3 M MgATP in FDB isolated fibers from WT, SUR2wt/AV and SUR2AV/AV mice. (B) Sample
traces of currents in zero (CTRL), 10−7 M glibenclamide (Glib) and 5 × 10−3 M MgATP in FDB fibers from WT, SUR2wt/AV
and SUR2AV/AV mice (n. patches = 30, 48, 55 from 3 muscles/3 mice per genotype, respectively). (C,D) Sensitivity to
inhibition by MgATP (C) or Glib (D) in FDB patches fro WT, SUR2wt/AV and SUR2AV/AV mice. Dat were fitted using the
Hill equation (see Table 1). Each experimental point represents the mean ± SEM of at least three patches. Data significantly
different as evaluated with one-way ANOVA and Bonferroni test (*** p < 0.001, * p < 0.05).
Table 1. Fitting parameters measured the concentration–r spons relationships of KATP currents amplitude vs. MgATP or
glibenclamide concentrations in FDB isolated fibers from WT, SUR2wt/AV a d SUR2AV/AV mice. Values are expressed as
the mean ± SEM of at least three replicates from 3 muscles/3 mice per genotype, as evaluated by using SigmaPlot 10. n.a.
indicates experimental conditions for which fitting parameters were not obtained.
MgATP Glibenclamide
Mice Emax (%) IC50 (M) Hill Slope Emax (%) IC50 (M) Hill Slope
WT −98.7 ± 0.7 8.6 ± 0.4 × 10−6 1.2 ± 0.1 −95.6 ± 1.9 1.2 ± 0.4 × 10−7 M 0.4 ± 0.05
SUR2WT/AV −95.6 ± 6 1.9 ± 0.5 × 10−5 0.9 ± 0.2 −97 ± 7.5 1.9 ± 2.2 × 10−7 M 0.25 ± 0.08
SUR2AV/AV n.a n.a. n.a. −102.5 ± 9 4.2 ± 3.7 × 10−6 M 0.26 ± 0.07
3.4. Marked Atrophy and Abnormal Morphology of SOL and TA Muscles
Histochemical evaluations were performed on slow-twitch soleus (SOL) (n. muscles
≥ 2 from ≥2 mice per genotype), fast-twitch gastrocnemius (GA) (n. muscles ≥ 2 from
≥2 mice r genotyp ), tibialis anterior (TA) (n. muscles ≥ 2 from ≥2 mice per g notype)
and extensor digitorum longus (EDL) (n. muscles ≥ 2 from ≥2 mice per genotype) muscles.
Hematoxylin–eosin (H.E.) stains indicated non-inflammatory edema in the endomysia
of GA and EDL muscles of SUR2AV/AV and SUR2wt/AV mice. The cross-sectional area
(CSA) of EDL (Figure 4A–C) and GA muscles (data not shown) did not differ significantly
between genotypes as evaluated by one-way ANOVA (p > 0.05). In contrast, CSA was pro-
gressively reduced, by ~5% and ~20% in SOL muscle from SUR2wt/AV and SUR2AV/AV mice,
respectively (Figure 5A–D), and this was associated with relatively small diameter myofibers
and the presence of inflammatory cells (n. inflammatory cells per sections = 15 ± 3, 20×)
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in the muscle of SUR2AV/AV mice, as well as some degenerative-necrotic areas (Figure 5D).
SOL muscle section of WT mice showed n. 9 ± 3 inflammatory cells per sections, 20×.
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muscles of (A) WT, (B,D,E) SUR2AV/AV and (C) SUR2wt/AV mice. (B) TA muscle from SUR2AV/AV mice showed heterogenous 
population of myofibers with reduced area (arrows) (10×, Bar 50 μm), (D) no longer polygonal in shape but elongated, 
rounded and angular, with hyper-eosinophil sarcoplasm (arrow) (H.E. 40×, Bar 50 μm). (E) Hyperchromatic nuclei can be 
grouped together, and present fragmented myo-fibers separated by an accumulation of pale pink interstitial material of 
inflammatory origin in TA muscle from SUR2AV/AV mice (H.E. 40×, Bar 50 μm). 
Figure 5. Sample representative histological analysis with hematoxylin–eosin (H.E.) reaction on soleus (SOL) muscles of (A)
WT, (B,D) SUR2AV/AV and (C) SUR2wt/AV mice. (B) SOL muscles from SUR2AV/AV mice showed marked atrophy (H.E.
10×, Bar 50 µm) vs. (A) WT and (C) SUR2wt/AV EDL muscles. (D) SOL muscle from SUR2AV/AV mice showed myofibers
with small diameter (arrow 1) and inflammatory cells (arrow 2) and rare area of degeneration and necrosis with some
atrophy (H.E. 20×, Bar 50 µm).
TA muscle showed even more severe atrophy, with reduced CSA of ~30% and ~40% in
TA of SUR2wt/AV and SUR2AV/AV mice, respectively (Figure 6A–C, Figure 7). In the muscle
TA of SUR2AV/AV mice, a heterogeneous population of myofibers with reduced area was
evident, with angular atrophic fibers alongside larger, rounded and slightly hypertrophic
fibers (Figure 6D,E), as well as interstices with edema and inflammatory cells (Figure 6E)
(n. inflammatory cells per sections = 18 ± 4, 20×). TA muscle section of WT mice showed
n. 7 ± 4 inflammatory cells per sections, 20×.
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Figure 7. Cross sectional area of tibialis anterior (TA) and soleus (SOL) muscles of CS mice. The CSA of TA muscle was
significantly reduced in CS mice, and it was 1937.5 ± 121 µm2 in heterozygous (F = 2.982, * p < 0.05) (n muscle/mice = 3/3)
and 1647.8 ± 131 µm2 in homozygous CS mice (F = 3.321, * p < 0.05) (n muscle/mice = 3/3) vs. 2769.6 ± 221 µm2 in WT mice
(n muscle/mice = 3/3). The CSA of SOL muscle was significantly reduced in homozygous mice, and it was 1142.7 ± 99 µm2
(F = 1.9821, * p < 0.05) (N mice = 2) vs. 1465 ± 91 µm2 in WT (n muscle/mice = 3/3). CSA was calculated on 53 fibers
per mouse.
Mallory trichrome and P.A.S. analysis with blue and magenta red color were negative
in all sampled muscles, including TA and SOL, suggesting the absence of connective tissues
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and glycogen accumulation, respectively, in the CS muscles. Additionally, the ATP-ASE
reaction to pH 4.3 and coloring of the myofibrils positive to the succinodehydrogenase
(SDH) was negative in the muscles analyzed, suggesting the lack of involvement of type I
fibers (n. muscles ≥ 2 from ≥2 mice per genotype).
In support to histological analysis, qPCR showed the up-regulation of FBXO32 and
TRIM63 (encoding atrogin-1 and MuRF1, respectively) in SOL and TA muscles from
SUR2wt/AV and in SUR2AV/AV mice with respect to the WT (Figure 8). Furthermore,
consistent with non-apoptotic death, no expression of Casp3 was detected in either WT,
SUR2wt/AV or SUR2AV/AV muscles (data not shown).
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of TA muscle was significantly reduced in CS mice, and it was 1937.5 ± 121 μm2 in heterozygous (F 
= 2.982, * p < 0.05) (n muscle/mice = 3/3) and 1647.8 ± 131 μm2 in homozygous CS mice (F = 3.321, * p 
< 0.05) (n muscle/mice = 3/3) vs. 2769.6 ± 221 μm2 in WT mice (n muscle/mice = 3/3). The CSA of SOL 
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Figure 8. Atrogin-1 and MuRF1 gene expression in soleus (SOL), tibialis anterior (TA) and gastrocnemius (GA) of WT, 
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Figure 8. Atrogin-1 and MuRF1 gene expression in soleus (SOL), tibialis anterior (TA) and gastrocnemius (GA) of WT,
SUR2wt/AV and SUR2AV/AV mice. The figure shows quantification of transcriptional level with qPCR for (A) atrogin-1 and
(B) MuRF1 normalized by β-actin gene. In each graph, bars represent mean ± SEM for 3 muscles per each genotype. * Data
significantly different with respect to the WT (p < 0.05).
3.5. Ex Vivo Survival of Skeletal Muscle Fibers from SUR2 Mutated Mice Is Reduced
Finally, we assessed the ex vivo survival of isolated FDB fibers in the three genotypes.
There was no marked difference in FDB survival rate within 3 h from the excision, but there
was markedly higher death of SUR2AV/AV FDB fibers within 24 h of excision, with a
viability reduction of ~30% with respect to the other two phenotypes. Consistent with a
pre-existing fiber weakness, inhibition of KATP by application of Glib did not strongly affect
the survival rate of WT and SUR2wt/AV fibers in short term incubation, instead slightly
worsening fiber survival in all the genotypes after 24 h of incubation (Figure 9).
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Figure 9. Evaluation of ex vivo survival of FDB isolated fibers from WT, SUR2wt/AV and SUR2AV/AV mice. Fiber survival
was reduced at 3 h in SUR2AV/AV fibers and progressively more so in SUR2wt/AV and SUR2AV/AV at 24 h. Short-time
incubation with Glib did not significantly affect fiber viability, whereas 24 h of fibers treatment with Glib further reduced
fiber viability with respect to untreated fibers (n. of fibers = 100–150 for each experimental condition; fibers were collected
from ≥ 3 FDB from ≥3 mice per genotype). Values of percentage of fiber survival are presented as individual data points for
each repetition. Data significantly different as evaluated with one-way ANOVA and Bonferroni test (*** p < 0.001, * p < 0.05).
4. isc ssio
In the present work we investigated the effects of the patient-specific Cantu sy drome
(CS) ABC 9 mutation SUR2[A478V] in different skeletal muscle types from SUR2wt/AV
and SUR2AV/AV CS mice, in which mutation was introduced to the equivalent locus i
the mouse genome [18]. Although CS mice were heavier than age-matched WT mice, we
found markedly impaired strength and muscle function in heterozygous, and more so
in homozygous, CS mice, similar to what is reported in human CS patients [3]. CS mice
generate significantly lower forelimb forces than WT, similar to the reduced force previously
observed in Kir6.1[V65M] mice [16,32], which carry a Kir6.1 CS mutation.
4.1. Skeletal Muscle Weakness in CS
A variety of muscles, including SOL, TA, FDB and diaphragm, with different physio-
logical roles, were similarly affected by the mutation, all showing atrophy and low fiber
survival ex vivo that contribute to the characteristic muscle phenotypes in vivo. Large inter-
myofiber areas appear to be formed by edema of not-inflammatory or lymphatic origin,
being negative to Mallory trichrome or markers of fibrosis and showing the presence of
inflammatory infiltrate. These histological changes, together with reduced muscle cross-
sectional area (CSA) and weight in SOL, and of CSA in TA, help to explain muscle weakness
yet enhanced hind-limb volume and mean echodensity evaluated by 3D ultrasonography.
Reduction of CSA and muscle weights in SOL but only of CSA in TA could be explained by
the deposition of interstitial material that masks the expected reduction of muscle weight.
Interstitial fat deposition cannot be excluded as a possible causative factor affecting muscle
function and morphology since the use of ethanol solvent in our histopathological analy-
sis excludes identification of adipose cells, which could potentially infiltrate the muscle.
We also observed a large reduction of the amplitude of diaphragm movement of SUR2wt/AV
and SUR2AV/AV mice, consistent with exercise intolerance and difficulty breathing that
has been reported in CS patients [3]; in our mice this was also associated with enhanced
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diaphragm echodensity. GA and EDL muscles were much less affected, with no change in
CSA or muscle weight, despite the presence of some edema of non-inflammatory origin.
This suggests that not all muscles are equally affected, and potentially that the specific
muscle function plays a role in determining the CS muscular phenotype.
Atrophy with reduction of CSA was observed in SOL and TA muscles, and reduced
ex vivo survival was observed in hetero and homozygous SUR2 FDB fibers. Interestingly,
this was not reversed or prevented by KATP channel inhibition by glibenclamide treatment
in vitro, suggesting a pre-existing muscle deficit.
4.2. The Cellular and Pharmacological Consequences in SUR2wt/AV and SUR2AV/AV Mice Muscles
Excised patch-clamp experiments revealed no significant increase of KATP current
density in FDB fibers of SUR2wt/AV and SUR2AV/AV CS mice but did indicate a significant
reduction of the sensitivity to inhibition by MgATP in the heterozygous and even more
so in the homozygous mice, which was at least as marked as previously seen in cardiac
myocytes [18], together with a minimal shift in glibenclamide sensitivity. Previously,
we showed only a small shift of the MgATP sensitivity in FDB and SOL patches from
Kir6.1wt/VM fibers, with a reduced response to Glib in FDB patches and loss of response
in SOL patches expressing the Kir6.1 subunit [16]. These findings are consistent with
the prominence of Kir6.2 and SUR2A (but not Kir6.1) in skeletal muscle KATP channels
function, a point we return to below.
4.3. Mechanistic Basis of CS Skeletal Muscle Pathology
KATP channels are abundant in cardiac, skeletal and vascular smooth muscle [33].
Skeletal muscle KATP channels are expected to open as [ATP]/[ADP] falls during repetitive
contractions, leading to hyperpolarization and action potential failure, which may limit
contractile force. All four KATP channel subunits are expressed in skeletal muscle, but the
major subunits are understood to be Kir6.2 (KCNJ11) and SUR2A (ABCC9) [17]. Kir6.2
knockout mice reveal rapidly fatiguing, weak muscles [34], indicating that the failure of
KATP to limit excitability results in fatigue and ultimately necrosis [35] as a consequence
of [Ca]-overload and energy depletion [36].
The underlying KATP channel genes are present as two distinct pairs (ABCC8/KCNJ11
and ABCC9/KCNJ8), on human chromosomes 11p and 12p, respectively. They are generally
expressed as these canonical pairs in specific tissues, and distinct human syndromes are
associated with mutations in each pair of genes; gain- (GOF) or loss-of-function (LOF)
mutations in either SUR1 or Kir6.2 cause congenital or neonatal diabetes, respectively [37].
Conversely, GOF mutations in either Kir6.1 or SUR2 cause Cantu syndrome (CS), with quite
different organ involvement [2,3,18]. The expression of non-canonical KATP channels
formed by Kir6.2 with SUR2A in skeletal and cardiac muscle would suggest the potential
for overlap of neonatal diabetes and Cantu syndrome pathologies in these tissues. How-
ever, there is essentially no cardiac and skeletal muscle phenotype in NDM patients [38],
despite reported altered muscle function [39], or in mice expressing Kir6.2 GOF specifi-
cally in the heart [40]. There is a striking cardiac phenotype in CS (massive enlargement
and hypercontractility) [18], but this is a secondary consequence of neuro-humoral feed-
back in response to the reduced systemic vascular resistance that results from overactive
Kir6.1/SUR2B channels in blood vessels [19].
SUR2A is the main KATP channel regulatory subunit in all skeletal types, and marked
changes in KATP currents are present in the SUR2[A478V] CS skeletal myocytes, poten-
tially underlying the pathologies observed. SUR2A and Kir6.2 subunits are prominently
expressed in TA and FDB WT rat muscles, generating a high KATP channel current density
in these muscles [17], thereby potentially increasing their susceptibility to the metabolic
uncoupling associated with GOF SUR2 CS mutations. SOL muscle is an oxidative muscle
that is more susceptible to metabolic stress than glycolytic muscles such as GA and EDL,
which are expected to face metabolic stress more efficiently.
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However, contribution of non-skeletal myocyte mechanisms to skeletal muscle pathol-
ogy is also possible. In this context, significant vascularization is observed in the CS
muscles, especially in homozygous SUR2AV/AV mice, and the potential involvement of
vascular or other smooth muscle derangements in the skeletal muscle phenotypes should
be considered. Previously, even though Kir6.1 is only a minor component of skeletal muscle
KATP, we showed that muscles from Kir6.1wt/VM CS mice also tended to be heavier than
WT, with significant increase of echodensity of hind limb muscles but also associated with a
tendency toward increased hind limb volume and mild extra-vascularization. Additionally,
histological analysis revealed marked atrophy of type I fibers with extended necrotic area
and replacement of the myofibers, suggesting damage to skeletal muscle integrity, along
with fibrous tissue deposition and infiltration of inflammatory cells, explaining increased
echodensity, decreased muscle strength and pseudo-hypertrophy [16]. As discussed above,
and consistent with only a minor role for Kir6.1 in skeletal muscle channels, the skeletal
muscle KATP GOF, as revealed by shifts in ATP sensitivity, were much less than in the
present study, even though the muscle pathology was similar.
This is reminiscent of parallel findings in the heart in which cardiac myocyte KATP
GOF is present in SUR2AV/AV but not Kir6.1wt/VM, yet pathologic enlargement and hy-
percontractility is greater in the latter [18]. It is explained by up-regulation of the renin–
angiotensin signaling pathway as a major mediator of feedback signaling from lowered
resistance in the systemic vasculature to drive cardiac enlargement and hypercontractil-
ity [41]. Thus, although overactivity of skeletal myocyte KATP channels might contribute
to atrophy, ACE/Ang II/ATR1 signaling is also a known mediator of atrophy and sar-
copenia in skeletal muscle [42] and a potential major driver of the muscle pathology.
Similarly, fiber damage may result in fluid leakage into the extracellular space, but the
nature of the observed fluid, combined with the demonstration that lymphatic contractility
can be markedly reduced by KATP GOF in lymphatic smooth muscle [43], further suggests
a non-skeletal myocyte, i.e., lymphatic smooth muscle [43], contributor to the edema that
characterizes the CS muscles.
This work aimed to investigate the KATP channel functionality in skeletal muscle
of CS mice so that the low number of mice limited the investigation of secondary end-
points. Future investigations having as a primary endpoint the evaluation of the molecular
pathways associated with this dysfunction will help to clarify this point.
5. Conclusions
The introduction of CS mutations on SUR2wt/AV and SUR2AV/AV mice, which strongly
reduces the sensitivity of skeletal muscle fibers to ATP inhibition, has marked effects on
the integrity and the functionality of skeletal muscles, leading to muscle weakness and
atrophy, paralleling findings in human CS patients. This and other SUR2 mutations do
not markedly affect the channel sensitivity to glibenclamide. Thus, as has been shown for
cardiovascular pathologies [19,41], glibenclamide treatment may help to reverse or avoid
these consequences.
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